Revenue: As of FY2025 Q3, the actual value is USD 2.855 K, missing the estimate of USD 150 K.EPS: As of FY2025 Q3, the actual value is USD -0.98.EBIT: As of FY2025 Q3, the actual value is USD -1.709 M, missing the estimate of USD -1.399 M.<h3>Segment Revenue</h3><ul><li>Product Test Sales: $11,270 for the nine months ended September 30, 2025, compared to $30,378 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $5,032,799 for the nine months ended September 30, 2025, compared to $6,864,145 for the same period in 2024.</li><li>Selling, General and Administrative Expenses: $5,032,126 for the nine months ended September 30, 2025, compared to $6,879,853 for the same period in 2024.</li><li>Research and Development Expense: $354,345 for the nine months ended September 30, 2025, compared to $23,367 for the same period in 2024.</li><li>Sales and Marketing Expense: $445,566 for the nine months ended September 30, 2025, compared to $144,240 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $4,364,984 for the nine months ended September 30, 2025, compared to $3,600,809 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: $340,951 for the nine months ended September 30, 2025, compared to $349,577 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $3,233,666 for the nine months ended September 30, 2025, compared to $4,649,453 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Cardio Diagnostics Holdings, Inc. plans to develop additional products, including clinical tests for stroke, congestive heart failure, and diabetes. The company also aims to offer laboratory services once their laboratory setup is complete and expand the adoption of their products across key channels, including health systems and self-insured employers.</li><li>Non-Core Business: The company is exploring additional market opportunities in the US and internationally and pursuing potential strategic partnerships and acquisitions of synergistic companies.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation Expense: $86,152 for the nine months ended September 30, 2025, compared to $2,568,753 for the same period in 2024.</li><li>Amortization Expense: $59,578 for the nine months ended September 30, 2025, compared to $14,389 for the same period in 2024.</li></ul>

Cardio Diagnostics | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 2.855 K